Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Tapiero

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Vaccine|October 19, 2006
An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccineJoanne M Langley, Gerald Predy, R Guasparini, et al.
The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses|December 27, 2007
Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatmentUpton Allen, Caroline Alfieri, Jutta Preiksaitis, et al.
Vaccine|December 8, 2010
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of ageFrancisco Diaz-Mitoma, Scott A Halperin, Bruce Tapiero, et al.
BMC Public Health|February 8, 2019
Promoting vaccination in the province of Québec: the PromoVaQ randomized controlled trial protocolArnaud Gagneur, Caroline Quach, François D Boucher, et al.
Human Vaccines & Immunotherapeutics|August 11, 2018
Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, CanadaÈve Dubé, Anne Farrands, Thomas Lemaitre, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 12, 2019
Promoting vaccination in maternity wards ─ motivational interview technique reduces hesitancy and enhances intention to vaccinate, results from a multicentre non-controlled pre- and post-intervention RCT-nested study, Quebec, March 2014 to February 2015Arnaud Gagneur, Marie-Claude Battista, François D Boucher, et al.
Vaccine|March 2, 2022
Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country studyYu-Lung Lau, Ting Fan Leung, Benhur Sirvan Cetin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2018
Pediatric Investigators Collaborative Network on Infections in Canada Study of Respiratory Syncytial Virus-associated Deaths in Pediatric Patients in Canada, 2003-2013Jennifer Tam, Jesse Papenburg, Sergio Fanella, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsHeather L Platt, David Greenberg, Bruce Tapiero, et al.
Vaccine|January 7, 2009
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of ageScott A Halperin, Bruce Tapiero, Francisco Diaz-Mitoma, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Vaccine|October 19, 2006
An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccineJoanne M Langley, Gerald Predy, R Guasparini, et al.
The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses|December 27, 2007
Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatmentUpton Allen, Caroline Alfieri, Jutta Preiksaitis, et al.
Vaccine|December 8, 2010
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of ageFrancisco Diaz-Mitoma, Scott A Halperin, Bruce Tapiero, et al.
BMC Public Health|February 8, 2019
Promoting vaccination in the province of Québec: the PromoVaQ randomized controlled trial protocolArnaud Gagneur, Caroline Quach, François D Boucher, et al.
Human Vaccines & Immunotherapeutics|August 11, 2018
Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, CanadaÈve Dubé, Anne Farrands, Thomas Lemaitre, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 12, 2019
Promoting vaccination in maternity wards ─ motivational interview technique reduces hesitancy and enhances intention to vaccinate, results from a multicentre non-controlled pre- and post-intervention RCT-nested study, Quebec, March 2014 to February 2015Arnaud Gagneur, Marie-Claude Battista, François D Boucher, et al.
Vaccine|March 2, 2022
Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country studyYu-Lung Lau, Ting Fan Leung, Benhur Sirvan Cetin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2018
Pediatric Investigators Collaborative Network on Infections in Canada Study of Respiratory Syncytial Virus-associated Deaths in Pediatric Patients in Canada, 2003-2013Jennifer Tam, Jesse Papenburg, Sergio Fanella, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsHeather L Platt, David Greenberg, Bruce Tapiero, et al.
Vaccine|January 7, 2009
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of ageScott A Halperin, Bruce Tapiero, Francisco Diaz-Mitoma, et al.
Pageof 5